Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)

Liver Cirrhoses Clinical Trial

Official title:

Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04057287
• Other study ID #: ILBS-NRC-01
• Status: Recruiting
• Start date: September 18, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: October 2023
• Source: Institute of Liver and Biliary Sciences, India
• Contact: Dr Ankit Bhardwaj, Masters-CR
• Phone: 01146300000
• Email: bhardwaj.ankit3[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study aim to identify the risk factors of liver fibrosis among first degree relatives. This study consists of 2 parts (Cross Sectional and Case Control Study).

Part 1: The first primary objective will be achieved by following study design. Study population: First degree relatives of NRC. Study design: A Cross Sectional Study

Part 2 The second Primary objective will be achieved by following study design. Study design:

A Case Control Study

Study population:

Case: NASH related Cirrhosis patients Control-1: Healthy Control. Control-2: HBV Disease Control Study period: 3 Years

All the patients diagnosed with NASH cirrhosis attending Institute of Liver and Biliary Sciences OPD/IPD will be enrolled. An informed consent will be taken. Complete details of the subject will be taken. The data will be collected on socio-demographic by (socio-demographic questionnaire), alcohol by AUDIT-C (Alcohol Use Disorders Identification Test), Tobacco by FTND (Fagerstrom Test Nicotine Dependence), physical activity by IPAQ (International Physical Activity Questionnaire), Diet by FFQ (Food Frequency Questionnaire), physical measurement & all the comorbidities.

Blood will be collected and analyzed for Platelets, PT/INR, Serum Creatinine, LFT, FBS, HOMA-IR, Lipid Profile, HBsAg, AntiHBs, Anti HBc, Anti HCV, Anti HAV, IgM anti HAV, IgM anti HEV, auto-Immune markers, Ceruloplasmin, Transferrin, S.Ferritin, Alpha1antitrpsin and genetic markers.

The stool will be collected and analyzed for gut microbiota profiling.

Description:

The data will be collected on socio-demographic by (socio-demographic questionnaire), alcohol by AUDIT-C (Alcohol Use Disorders Identification Test), Tobacco by FTND (Fagerstrom Test Nicotine Dependence), physical activity by IPAQ (International Physical Activity Questionnaire), Diet by FFQ (Food Frequency Questionnaire), 24-hour dietary recall method, physical measurement & all the comorbidities.

Blood will be collected and analyzed for CBC, LFT, KFT, PT/INR, FBS, HOMA-IR, Lipid Profile, HBsAg, AntiHBs, Anti HBc, Anti HCV, Anti HAV, IgM anti HAV, IgM anti HEV, auto-Immune markers, Ceruloplasmin, Transferrin, S.Ferritin, Alpha1antitrpsin and genetic markers.

The stool will be collected and analyzed for gut microbiota profiling. Controlled Attenuation Parameter and liver stiffness will be measured by using transient elastography. Ultrasound abdomen will be done First degree relatives of indexed patients will be enrolled. First degree relatives who will not accompanying the indexed subject will be contacted telephonically and will be requested to participate in the study.

The data on first degree relative will be collected on similar parameter as of the indexed patient. This will be a cross sectional study.

For each case, 1 healthy controls will be taken. Healthy Control will be identified from the OPD/IPD of ILBS. Liver transplant donors, hospital volunteers, Blood Donors, healthy attendants who are accompanying other patients of different specialties will be enrolled. An informed consent will be taken. The data will be collected on similar parameter as of the indexed patient. This will be case control study.

We will also have disease control (HBV control) for each case enrolled. Subject suffering from Hepatitis B virus related liver cirrhosis will be included as disease control. For each case, 1 disease control will be included. Disease Control will be identified from the OPD/IPD of ILBS. An informed consent will be taken. The data will be collected on similar parameter as of the indexed patient.

Genetic markers and stool microbiota profiling will be done in 30% of the subsets of sample i.e NASH related Cirrhosis, First Degree Relatives, Healthy Control and HBV Disease control.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 670
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for NASH related Cirrhosis (Group 1-Index Case)

1. Age =18 yrs

2. Diagnosed cases of NASH with Cirrhosis.

Exclusion Criteria for NASH related Cirrhosis (Group 1)

1. Acute on Chronic Liver Failure

2. Patients with HBV, HCV, Wilson's, Hemochromatosis, alpha 1 antitrypsin deficiency, primary biliary cirrhosis).

3. Patient on treatment with amiodarone or methotrexate.

4. Patient with any malignancies

5. Patient on chemotherapy

Inclusion Criteria for First Degree Relatives (Group 2)

1. Age =8 yrs

2. All the first degree relatives of index case.

Exclusion Criteria for First Degree Relatives (Group 2)

1. Alcohol intake

Inclusion Criteria for Healthy Control (Group 3)

1. Age =18 yrs

2. Subjects with no history of any known liver disease

3. Non-Alcoholic

4. Matched with Age (+/- 5 yrs.) and Gender

Exclusion Criteria for Healthy Control (Group 3)

1. None

Inclusion Criteria for HBV Disease Control (Group 4)

1. Age =18 yrs

2. HBV Cirrhosis

3. Matched with Age (+/- 5 yrs.) and Gender

Exclusion Criteria for HBV Disease Control (Group 4)

1. Patient with any malignancies

2. HBV related Liver Fibrosis (= F3).

Related Conditions & MeSH terms

• Fibrosis
• Liver Cirrhoses
• Liver Cirrhosis

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
India	Institute of Liver and Biliary Sciences	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and their First Degree Relatives.		Day 0
Primary	Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and Healthy Control group.		Day 0
Primary	Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) & 24 hour dietary recall method between NASH related cirrhosis and their First Degree Relatives.		Day 0
Primary	Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) & 24 hour dietary recall method between NASH related cirrhosis and Healthy Control group		Day 0
Primary	Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and their First Degree Relatives.		Day 0
Primary	Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and Healthy Control group		Day 0
Primary	Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and their 1st degree relatives.		Day 0
Primary	Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and Healthy Control group.		Day 0
Primary	Metabolic syndrome as risk factors between NASH cirrhosis and their First Degree Relatives.		Day 0
Primary	Metabolic syndrome as risk factors between NASH cirrhosis and healthy Control		Day 0
Secondary	Proportion of Liver fibrosis among first degree relatives of patients with NASH related Cirrhosis.		Day 0
Secondary	Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and HBV disease control.		Day 0
Secondary	Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) and 24 hours dietary recall method between NASH related cirrhosis and HBV disease control.		Day 0
Secondary	Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and HBV disease control.		Day 0
Secondary	Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and HBV disease control.		Day 0
Secondary	Metabolic syndrome as risk factors between NASH cirrhosis and HBV Cirrhosis		Day 0